Quince Therapeutics, Inc. Common Stock (QNCX) Stock
NASDAQ · QNCX
29.70
Fundamentals
Market cap
$31.53M
Price / Earnings ratio
-0.3x
Price / Sales ratio
N/A
Price / Book ratio
-0.9x
Return on assets
-38.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Stocktwits
QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger
NeutralQNCXMarch 30, 2026
StocktwitsNeutral
QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger
QNCX

Business Wire
Quince Therapeutics Settles Approximately $16.4 Million of Debt
NeutralQNCXMarch 30, 2026
Business WireNeutral
Quince Therapeutics Settles Approximately $16.4 Million of Debt
QNCX

Business Wire
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
NeutralQNCXFebruary 9, 2026
Business WireNeutral
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
QNCX

Stocktwits
Why Did QNCX Stock Plummet Over 90% Today?
NeutralQNCXJanuary 29, 2026
StocktwitsNeutral
Why Did QNCX Stock Plummet Over 90% Today?
QNCX
Technicals
OscillatorsBuy5 Indicators
Moving AveragesSell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy4
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Stocktwits
QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger
NeutralQNCXMarch 30, 2026
StocktwitsNeutral
QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger
QNCX

Business Wire
Quince Therapeutics Settles Approximately $16.4 Million of Debt
NeutralQNCXMarch 30, 2026
Business WireNeutral
Quince Therapeutics Settles Approximately $16.4 Million of Debt
QNCX

Business Wire
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
NeutralQNCXFebruary 9, 2026
Business WireNeutral
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
QNCX

Stocktwits
Why Did QNCX Stock Plummet Over 90% Today?
NeutralQNCXJanuary 29, 2026
StocktwitsNeutral
Why Did QNCX Stock Plummet Over 90% Today?
QNCX

Business Wire
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
NeutralQNCXJanuary 29, 2026
Business WireNeutral
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
QNCX

Business Wire
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
NeutralQNCXJanuary 28, 2026
Business WireNeutral
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
QNCX

Business Wire
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
NeutralQNCXDecember 15, 2025
Business WireNeutral
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
QNCX

Business Wire
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
NeutralQNCXDecember 10, 2025
Business WireNeutral
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
QNCX

Business Wire
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
NeutralQNCXAugust 7, 2025
Business WireNeutral
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
QNCX

PennyStocks
How to Identify Potentially Profitable Penny Stocks to Buy
NeutralQNCXJanuary 29, 2023
PennyStocksNeutral
How to Identify Potentially Profitable Penny Stocks to Buy
QNCX
About Quince Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees38
CEODr. Dirk Thye M.D.
IPO DateMay 9, 2019
HeadquartersSouth San Francisco, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Dirk Thye M.D. | CEO, Chief Medical Officer & Director | 1970 |
| Dr. Charles S. Ryan J.D., Ph.D. | President | 1964 |
| Mr. Brendan Hannah M.B.A. | Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer | 1986 |
| Dr. Guenter R. Janhofer M.D., Ph.D. | Chief Scientific Officer | — |
| Dr. Brigette Roberts M.D. | Chief Corporate Affairs Officer & Director | 1975 |
| Dr. Keith R. Fandrick Ph.D. | Head of Technical Operations | 1979 |
| Mr. John C. Militello CPA | Head of Finance | 1973 |
Fundamentals
Valuation
Market cap$31.53M
Price-to-sales ratioN/A
Price-to-book value-0.86
Price-earnings ratio-0.30
Return on Equity1824.00%
Return on SalesN/A
Return on Assets-38.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-142.31
Income Statement
Average volume20,159
EBITDA$-35.06M
1 year high (52w)$35.41
1 year low (52w)$0.08
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesSell12 Indicators
What the experts say
4 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$74.75
Est return
145.73%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -12.4 | -19.4 | -19.4 | -24.5 | -14.7 | |||||||
| 2023 | +36.1 | -1.1 | +64.2 | -13.6 | -4.5 | +5.6 | -18.4 | +8.3 | -13.8 | -9.3 | -8.2 | +9.4 |
| 2024 | +19.2 | -0.8 | -17.2 | -1.8 | -16.2 | -14.8 | +2.7 | -6.8 | +13.0 | +107.7 | +33.1 | -10.1 |
| 2025 | -14.4 | -9.4 | -8.3 | -13.4 | -3.7 | +55.7 | +11.2 | -4.8 | +1.9 | +1.9 | +123.9 | +5.7 |
| 2026 | -94.3 | -27.8 | +0.0 | +31.0 | -13.5 | -18.1 | +39.6 | +30.4 | -3.5 |
Corporate actions
Upcoming
No upcoming corporate actions for QNCX
Past
Reverse stock split
Split date30 Jun 2026
Ratio20 : 1
Reverse stock split
Split date13 Apr 2026
Ratio10 : 1



